The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach

J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S85-91. doi: 10.1016/j.jaad.2005.10.052.


Psoriatic arthritis is a common inflammatory arthritis associated with psoriasis, occurring in 5% to 40% of patients with cutaneous disease. Recently, there has been an increased appreciation of the need to use an integrated approach to these 2 diseases, considering both entities when determining therapeutic choices. In this review, the available therapeutic options for psoriatic arthritis are considered, along with the potential benefit that these medications may have for cutaneous psoriasis. Finally, a conceptual model for the therapy of psoriasis and psoriatic arthritis, the Four Quadrant Model, is presented as a simplified framework to use when considering treatment for psoriatic disease.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Arthritis, Psoriatic / drug therapy*
  • Arthritis, Rheumatoid / drug therapy
  • Cyclosporine / therapeutic use
  • Disease Progression
  • Etanercept
  • Etretinate / therapeutic use
  • Humans
  • Immunoglobulin G / therapeutic use
  • Immunosuppressive Agents / therapeutic use
  • Infliximab
  • Keratolytic Agents / therapeutic use
  • Methotrexate / therapeutic use
  • Psoriasis / drug therapy*
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Tumor Necrosis Factor-alpha


  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Keratolytic Agents
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Etretinate
  • Cyclosporine
  • Infliximab
  • Adalimumab
  • Etanercept
  • Methotrexate